223 related articles for article (PubMed ID: 36787187)
1. Active enterohepatic cycling is not required for the choleretic actions of 24-norUrsodeoxycholic acid in mice.
Truong JK; Li J; Li Q; Pachura K; Rao A; Gumber S; Fuchs CD; Feranchak AP; Karpen SJ; Trauner M; Dawson PA
JCI Insight; 2023 Mar; 8(6):. PubMed ID: 36787187
[TBL] [Abstract][Full Text] [Related]
2. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice.
Halilbasic E; Fiorotto R; Fickert P; Marschall HU; Moustafa T; Spirli C; Fuchsbichler A; Gumhold J; Silbert D; Zatloukal K; Langner C; Maitra U; Denk H; Hofmann AF; Strazzabosco M; Trauner M
Hepatology; 2009 Jun; 49(6):1972-81. PubMed ID: 19475687
[TBL] [Abstract][Full Text] [Related]
3. Secretin activation of the apical Na+-dependent bile acid transporter is associated with cholehepatic shunting in rats.
Alpini G; Glaser S; Baiocchi L; Francis H; Xia X; Lesage G
Hepatology; 2005 May; 41(5):1037-45. PubMed ID: 15834929
[TBL] [Abstract][Full Text] [Related]
4. Bile acids stimulate cholangiocyte fluid secretion by activation of transmembrane member 16A Cl
Li Q; Dutta A; Kresge C; Bugde A; Feranchak AP
Hepatology; 2018 Jul; 68(1):187-199. PubMed ID: 29360145
[TBL] [Abstract][Full Text] [Related]
5. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
[TBL] [Abstract][Full Text] [Related]
6. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans.
Hofmann AF; Zakko SF; Lira M; Clerici C; Hagey LR; Lambert KK; Steinbach JH; Schteingart CD; Olinga P; Groothuis GM
Hepatology; 2005 Dec; 42(6):1391-8. PubMed ID: 16317695
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice.
Fickert P; Pollheimer MJ; Silbert D; Moustafa T; Halilbasic E; Krones E; Durchschein F; Thüringer A; Zollner G; Denk H; Trauner M
J Hepatol; 2013 Jun; 58(6):1201-8. PubMed ID: 23369794
[TBL] [Abstract][Full Text] [Related]
8. Bile acid interactions with cholangiocytes.
Xia X; Francis H; Glaser S; Alpini G; LeSage G
World J Gastroenterol; 2006 Jun; 12(22):3553-63. PubMed ID: 16773712
[TBL] [Abstract][Full Text] [Related]
9. Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis.
Meadows V; Marakovits C; Ekser B; Kundu D; Zhou T; Kyritsi K; Pham L; Chen L; Kennedy L; Ceci L; Wu N; Carpino G; Zhang W; Isidan A; Meyer A; Owen T; Gaudio E; Onori P; Alpini G; Francis H
Am J Physiol Gastrointest Liver Physiol; 2023 Jan; 324(1):G60-G77. PubMed ID: 36410025
[TBL] [Abstract][Full Text] [Related]
10. New therapies target the toxic consequences of cholestatic liver disease.
Jansen PLM
Expert Rev Gastroenterol Hepatol; 2018 Mar; 12(3):277-285. PubMed ID: 29310470
[TBL] [Abstract][Full Text] [Related]
11. 24-Norursodeoxycholic acid reshapes immunometabolism in CD8
Zhu C; Boucheron N; Müller AC; Májek P; Claudel T; Halilbasic E; Baazim H; Lercher A; Viczenczova C; Hainberger D; Preglej T; Sandner L; Alteneder M; Gülich AF; Khan M; Hamminger P; Remetic J; Ohradanova-Repic A; Schatzlmaier P; Donner C; Fuchs CD; Stojakovic T; Scharnagl H; Sakaguchi S; Weichhart T; Bergthaler A; Stockinger H; Ellmeier W; Trauner M
J Hepatol; 2021 Nov; 75(5):1164-1176. PubMed ID: 34242699
[TBL] [Abstract][Full Text] [Related]
12. Characterization of ursodeoxycholic and norursodeoxycholic acid as substrates of the hepatic uptake transporters OATP1B1, OATP1B3, OATP2B1 and NTCP.
König J; Klatt S; Dilger K; Fromm MF
Basic Clin Pharmacol Toxicol; 2012 Aug; 111(2):81-6. PubMed ID: 22333292
[TBL] [Abstract][Full Text] [Related]
13. The choleretic effects of N-acetylglucosaminides, major urinary metabolites of ursodeoxycholic acid, in bile fistula rats.
Iwaki T; Hirabayashi N; Miyazawa N; Takeuchi Y; Ishizaki K; Sakakura H; Kasai H; Maeda M; Araki T
Eur J Pharmacol; 1998 Dec; 363(1):41-8. PubMed ID: 9877080
[TBL] [Abstract][Full Text] [Related]
14. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
[TBL] [Abstract][Full Text] [Related]
15. 24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis.
Sombetzki M; Fuchs CD; Fickert P; Österreicher CH; Mueller M; Claudel T; Loebermann M; Engelmann R; Langner C; Sahin E; Schwinge D; Guenther ND; Schramm C; Mueller-Hilke B; Reisinger EC; Trauner M
J Hepatol; 2015 Apr; 62(4):871-8. PubMed ID: 25463533
[TBL] [Abstract][Full Text] [Related]
16. The influences of cholecystectomy on the circadian rhythms of bile acids as well as the enterohepatic transporters and enzymes systems in mice.
Zhang F; Duan Y; Xi L; Wei M; Shi A; Zhou Y; Wei Y; Wu X
Chronobiol Int; 2018 May; 35(5):673-690. PubMed ID: 29381405
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of ursodeoxycholic acid- and canrenoate-induced biliary bicarbonate secretion and the effect on glucose- and amino acid-induced cholestasis.
Omland E; Mathisen O
Scand J Gastroenterol; 1991 May; 26(5):513-22. PubMed ID: 1871544
[TBL] [Abstract][Full Text] [Related]
18. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
Fickert P; Wagner M; Marschall HU; Fuchsbichler A; Zollner G; Tsybrovskyy O; Zatloukal K; Liu J; Waalkes MP; Cover C; Denk H; Hofmann AF; Jaeschke H; Trauner M
Gastroenterology; 2006 Feb; 130(2):465-81. PubMed ID: 16472600
[TBL] [Abstract][Full Text] [Related]
19. The heteromeric organic solute transporter alpha-beta, Ostalpha-Ostbeta, is an ileal basolateral bile acid transporter.
Dawson PA; Hubbert M; Haywood J; Craddock AL; Zerangue N; Christian WV; Ballatori N
J Biol Chem; 2005 Feb; 280(8):6960-8. PubMed ID: 15563450
[TBL] [Abstract][Full Text] [Related]
20. Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases.
Halilbasic E; Steinacher D; Trauner M
Dig Dis; 2017; 35(3):288-292. PubMed ID: 28249255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
